RADNOR, Pa. , Aug. 20, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.
ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") ( NASDAQ: MGNX ) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024 , inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024 .
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.
by calling (484) 270-1453 or by email at info@ktmc.com . Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.
be/toOTecvIuus DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements concerning the company's TAMARACK Phase 2 study of its drug vobramitamab duocarmazine (vobra duo) in patients with resistant prostate cancer. Specifically, the complaint alleges that Defendants' statements created a materially misleading impression concerning the safety profile of vobra duo and the totality of the Phase 2 TAMARACK study data. THE LEAD PLAINTIFF PROCESS: MacroGenics investors may, no later than Septemb.